Predictors of responses to immune checkpoint blockade in advanced melanoma

DSpace/Manakin Repository

Predictors of responses to immune checkpoint blockade in advanced melanoma

Citable link to this page

 

 
Title: Predictors of responses to immune checkpoint blockade in advanced melanoma
Author: Jacquelot, N.; Roberti, M. P.; Enot, D. P.; Rusakiewicz, S.; Ternès, N.; Jegou, S.; Woods, D. M.; Sodré, A. L.; Hansen, M.; Meirow, Y.; Sade-Feldman, M.; Burra, A.; Kwek, S. S.; Flament, C.; Messaoudene, M.; Duong, C. P. M.; Chen, L.; Kwon, B. S.; Anderson, A. C.; Kuchroo, V. K.; Weide, B.; Aubin, F.; Borg, C.; Dalle, S.; Beatrix, O.; Ayyoub, M.; Balme, B.; Tomasic, G.; Di Giacomo, A. M.; Maio, M.; Schadendorf, D.; Melero, I.; Dréno, B.; Khammari, A.; Dummer, R.; Levesque, M.; Koguchi, Y.; Fong, L.; Lotem, M.; Baniyash, M.; Schmidt, H.; Svane, I. M.; Kroemer, G.; Marabelle, A.; Michiels, S.; Cavalcanti, A.; Smyth, M. J.; Weber, J. S.; Eggermont, A. M.; Zitvogel, L.

Note: Order does not necessarily reflect citation order of authors.

Citation: Jacquelot, N., M. P. Roberti, D. P. Enot, S. Rusakiewicz, N. Ternès, S. Jegou, D. M. Woods, et al. 2017. “Predictors of responses to immune checkpoint blockade in advanced melanoma.” Nature Communications 8 (1): 592. doi:10.1038/s41467-017-00608-2. http://dx.doi.org/10.1038/s41467-017-00608-2.
Full Text & Related Files:
Abstract: Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.
Published Version: doi:10.1038/s41467-017-00608-2
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605517/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491966
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters